

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
1	17/LO/1875	219487	Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)	Yes	13/01/2020	28	47	75	05/04/2017	30/10/2019	08/01/2018	05/11/2019	27/11/2019	11/12/2019			
2	17/SC/0039	220282	MAGPIE	No					21/10/2019	12/02/2020	18/04/2017				B - Suspended by sponsor	Project setup halted due to covid	Neither
3	18/EE/0275	229033	(COMBIVAS)	Yes	23/09/2020	26	203	229	27/05/2019	07/02/2020	04/12/2018	25/02/2020	04/03/2020		B - Suspended by sponsor	Recruitment halted due to COVID	Neither
4	18/EM/0406	250403	The EURO-SHOCK Trial version 1	Yes	43899	27	130	157	03/10/2018	04/10/2019	04/03/2019	43768	43769	43774	F - No patients seen	This is a rare disease study, covered by the Musketeers? Memorandum with no site targets?	Neither
5	18/ES/0119	245233	Stopping Aminosalicilate Therapy in Inactive Crohn's Disease (STATIC)	No		101			07/11/2018	28/10/2019	09/11/2018	17/01/2020	06/02/2020		B - Suspended by sponsor	Recruitment halted due to COVID	Neither
6	18/LO/0660	237150	REMAP-CAP	Yes	43955	5	6	11	07/04/2020	23/04/2020	23/07/2018	43944	43949	43950	D - Sponsor Delays	Sponsor Green light delay	Sponsor
7	18/LO/1290	249002	Hookipa H-100-002	No		60			12/01/2018	25/11/2019	06/11/2018	20/01/2020	24/01/2020	29/01/2020	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
8	18/NE/0052	234786	Avacopan in Patients with C3 Glomerulopathy	No					25/07/2019	17/12/2019	24/04/2018				B - Suspended by sponsor	Project setup halted due to covid	Neither
9	18/NW/0031	230387	NET-02	No					10/03/2018	04/03/2020	08/02/2018	03/03/2020			B - Suspended by sponsor	Project setup halted due to covid	Neither
10	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	Yes	43880	15	119	134	03/09/2019	08/10/2019	07/12/2018	43759	43761	43808			
11	18/NW/0765	250220	Testing a novel aid to diagnosis of peritonitis in clinic v1	Yes	05/07/2020	0	146	146	21/08/2018	10/02/2020	01/04/2019	07/02/2020	10/02/2020		B - Suspended by sponsor	Recruitment halted due to COVID	Neither
12	18/SC/0427	220853	The Bronchiolitis Endotracheal Surfactant Study (BESS)	Yes	43782	27	16	43	10/07/2019	01/10/2019	15/10/2018	43741	43766	43782	C - Closed by sponsor	Withdrawn by sponsor	Sponsor
13	18/SC/0472	234266	ProMPT-2	No		14			28/05/2019	14/02/2020	24/10/2018	11/02/2020	28/02/2020		B - Suspended by sponsor	Recruitment halted due to COVID	Neither
14	18/SC/0580	235355	FROSTTIE	No					19/02/2020	02/06/2020	19/12/2018				B - Suspended by sponsor	Project setup halted due to covid	Neither
15	18/SS/0120	233867	DENIM / Dendritic cell Immunotherapy for Mesothelioma	No		1			28/09/2017	08/10/2019	08/10/2019	09/10/2019	09/10/2019	15/10/2019			
16	19/EE/0286	255237	Mepolizumab for COPD Hospital Eosinophilic admissions Pragmatic trial1	No		10			13/09/2019	04/02/2020	12/12/2019	43872	43875		F - No patients seen	tight Inclusion Criteria(Niche population)	Neither
17	19/EE/0327	270157	inRange	No					22/10/2019	10/03/2020	13/02/2020				B - Suspended by sponsor	Project setup halted due to covid	Neither
18	19/EM/0063	253607	AMADEUS	Yes	43945	91	98	189	06/02/2019	18/10/2019	14/05/2019	43839	43847	43852	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
19	19/EM/0221	261147	Feasibility of low energy diet in HFpEF and type 2 diabetes	No		148			19/02/2019	01/10/2019	13/09/2019	23/01/2020	26/02/2020	28/02/2020	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
20	19/EM/0258	266702	Fluids Exclusively Enteral from Day 1 (FEED1)	Yes	43796	27	7	34	10/09/2019	24/10/2019	13/09/2019	43773	43789	43790			
21	19/EM/0267	262581	SPACE FOR COPD maintenance	Yes	20/11/2019	0	41	41	11/11/2018	10/10/2019	10/10/2019	10/10/2019	10/10/2019	16/10/2019			
22	19/EM/0282	242364	ARTEMIS-IGAN	No					27/08/2019	24/02/2020	06/12/2019				B - Suspended by sponsor	Project setup halted due to covid	Neither

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
23	19/EM/0290	263656	Home-based exercise in Renal Transplant patients: The ECSERT Study	Yes	09/03/2020	9	39	48	15/04/2019	21/01/2020	14/10/2019	23/01/2020	30/01/2020	30/01/2020			
24	19/EM/0299	265496	Real-time Remote Echo Mentoring	No		12			09/07/2019	27/02/2020	24/02/2020	43697	43900	43900			
25	19/EM/0334	257450	Safety and Activity of Sparsentan in the Treatment of IgA Nephropathy	No					29/11/2019	08/01/2020	07/01/2020				D - Sponsor Delays	waiting for the partially signed agreement (updated April 2019)	Sponsor
26	19/LO/0343	255538	The PRECISE study	Yes	43872	36	69	105	13/08/2019	29/10/2019	12/08/2019	43761	43803	43804			
27	19/LO/0571	256756	Benralizumab Exacerbation Study	No		0			23/11/2018	08/10/2019	22/01/2020	08/10/2019	08/10/2019	17/01/2020	F - No patients seen	No Eligible patient available	Neither
28	19/LO/0738	258589	TURING	No		21			28/10/2019	07/02/2020	14/06/2019		43889		B - Suspended by sponsor	Recruitment halted due to COVID	Neither
29	19/LO/0966	262945	Provention Bio's T1D Trial Evaluating C-Peptide with Teplizumab	No		2			05/08/2019	04/02/2020	26/07/2019	05/11/2019	06/02/2020	11/03/2020			
30	19/LO/1500	269558	BASIC Study PMCF	No		79			12/09/2019	30/10/2019	29/10/2019	43804	43847	43851	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
31	19/LO/1921	271139	Belantamab Mafodotin in newly diagnosed multiple myeloma	No		34			15/08/2019	05/02/2020	03/02/2020	25/02/2020	10/03/2020		B - Suspended by sponsor	Recruitment halted due to COVID	Neither
32	19/NE/0110	257719	Precision medicine with zibotentan in microvascular angina (PRIZE)	No					07/10/2019	04/03/2020	04/12/2019				B - Suspended by sponsor	Project setup halted due to covid	Neither
33	19/NW/0302	255677	VIP Study	Yes	25/02/2020	100	34	134	21/05/2019	14/10/2019	05/07/2019	29/10/2019	22/01/2020	23/01/2020	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
34	19/NW/0570	234906	Efficacy and safety of LNP023 compared with rituximab in iMN	No		0			22/03/2019	05/12/2019	28/10/2019	43797	43804	43858			
35	19/SC/0107	237804	ANICCA-Class II	No		28			14/02/2018	17/10/2019	05/07/2019	01/11/2019	14/11/2019	18/11/2019			
36	19/SC/0418	261435	The RESET study - version 1.0	Yes	43895	52	56	108	16/09/2019	18/11/2019	24/09/2019	43837	43839	43844	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
37	19/SC/0566	265559	WAX	Yes	02/09/2020			194	21/02/2020	21/02/2020	02/12/2019	30/06/2020			B - Suspended by sponsor	Project setup halted due to covid	Neither
38	19/SS/0067	260562	BSET-Conformable EndoVascular Aneurysm Repair (CLEVAR) registry v1.0	No		21			11/09/2019	23/12/2019	30/05/2019	43839	43843	43895	B - Suspended by sponsor	Recruitment halted due to COVID	Neither
39	19/WA/0325	266292	EASY-AS	No		67			13/08/2019	19/12/2019	02/12/2019	16/01/2020	24/02/2020	04/03/2020	F - No patients seen	No Eligible patient available	Neither
40	19/WM/0178	262396	Multi-sited, mainstreaming of the term Snuby? to all types of births	Yes	43808	15	26	41	04/03/2019	29/10/2019	25/07/2019	43767	43782	43782			
41	19/WM/0308	268333	Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof of concept study	No					17/06/2019	30/03/2020	29/10/2019				B - Suspended by sponsor	Project setup halted due to covid	Neither
42	19/WS/0188	270378	ARISE-HF	No					05/03/2020	05/03/2020	14/02/2020				B - Suspended by sponsor	Project setup halted due to covid	Neither
43	19/YH/0269	259860	The 'SIT and be FIT' study - Version 1.0	Yes	02/01/2020	52	31	83	11/09/2019	11/10/2019	09/09/2019	13/11/2019	02/12/2019	05/12/2019			
44	19/YH/0400	271539	DIAMOND Study	No					29/01/2020	29/01/2020	09/01/2020	44007			B - Suspended by sponsor	Project setup halted due to covid	Neither
45	20/EE/0101	281712	RECOVERY trial	Yes	06/04/2020	14	6	20	17/03/2020	17/03/2020	17/03/2020	13/03/2020	31/03/2020	31/03/2020			
46	20/EM/0003	269023	SurfON	Yes	44077	112	70	182	27/09/2019	05/03/2020	14/02/2020	43994	44007		B - Suspended by sponsor	Recruitment halted due to COVID	Neither

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
47	20/HRA/1696	282338	RECOVERY - Respiratory Support	Yes	23/04/2020	11	3	14	08/04/2020	09/04/2020	03/04/2020	20/04/2020	20/04/2020	21/04/2020	F - No patients seen	PI3K gene amplification so quite a 'tight eligibility but hope to fulfil target	Neither
48	20/NW/0168	281317	SARS-CoV-2 infection	Yes	43927	9	12	21	16/03/2020	16/03/2020	17/03/2020	43914	43915	43915	F - No patients seen	Musketeers Memorandum Agreement	Neither
49	20/SC/0153	271051	The ASTUTE Trial	No					24/03/2020	12/05/2020					B - Suspended by sponsor	Project setup halted due to covid	Neither
50	20/SC/0201	282769	COVID-19 - ACCORD-2	Yes	44020	12	57	69	29/04/2020	30/04/2020	28/04/2020	43958	43963	43970			
51	20/SS/0057	281986	STOP-COVID19	Yes	13/07/2020	38	31	69	05/05/2020	05/05/2020	22/05/2020	05/06/2020	12/06/2020		F - No patients seen	Many thanks for confirming that we can commence recruitment to this study. As discussed previously this is a pilot study examining a rare condition, with a national recruitment target of 30 over 1 year. Our local recruitment target is 1 per year. It is extremely unlikely that we will recruit within the next 30 days, and the study should be exempted from this target. Best wishes Penny Dr Penny McParland Consultant Obstetrician	Neither
52	20/WM/0117	276905	Dapagliflozin, Exercise Training and physical function: the DETA trial	No					29/01/2020	10/06/2020	02/06/2020				B - Suspended by sponsor	Project setup halted due to covid	Neither
53	20/WM/0153	282437	COVID-MASK_v1.0	No		5			12/05/2020	04/06/2020	02/06/2020	09/06/2020	09/06/2020	10/06/2020			
54	20/WS/0062	256875	ACCEPTANCE, version 1	No					20/05/2020	04/06/2020	20/05/2020				B - Suspended by sponsor	Project setup halted due to covid	Neither
55	20/WS/0070	275797	FINEARTS-HF (Finerenone trial in patients with Heart Failure)	No					21/04/2020	17/06/2020	04/06/2020				B - Suspended by sponsor	Project setup halted due to covid	Neither
56	20/YH/0123	263968	The CONTROL Study	No					11/09/2019	04/06/2020	01/06/2020				B - Suspended by sponsor	Project setup halted due to covid	Neither
57	20/YH/0177	273999	SALT - The effect of increased sodium intake with a carbohydrate-rich meal on glucose homeostasis in subjects without diabetes after bariatric surgery.	No					06/02/2020	07/05/2020	29/06/2020				D - Sponsor Delays	Project setup halted due to covid	Neither

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
58	18/SC/0634	233709	STELLAR: A phase II, randomised study of CHOP-R in combination with acalabrutinib compared to CHOP-R in patients with newly diagnosed Richter's Syndrome (RS) and a platform for initial investigations into activity of novel treatments in relapsed/refractory and newly diagnosed RS.	Yes	44082	20	19	39	02/08/2019	31/07/2020	31/01/2019	44049	44063	44076			
59	18/SC/0015	236685	A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIa and IIb (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	No		0			01/05/2019	15/09/2020	23/02/2018	02/09/2020	15/09/2020				
60	18/WA/0239	243333	Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)	No					05/03/2020	23/09/2020	21/12/2018						
61	19/NW/0135	252254	An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	No		61			01/07/2019	31/07/2020	17/05/2019		30/09/2020	12/10/2020	D - Sponsor Delays	Delay in Contract negotiations	Sponsor
62	19/EE/0174	255746	The third Multi-Centre Intra-Pleural Sepsis Trial (MIST-3): Early Video Assisted Thoracoscopic Surgery (VATS) or Intrapleural Enzyme Therapy (IET) in Pleural infection - a feasibility, randomised trial	No					24/09/2020	24/09/2020	30/07/2019						
63	19/SC/0416	269256	A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)	Yes	08/10/2020	42	45	87	16/04/2020	13/07/2020	04/10/2019	11/08/2020	24/08/2020	01/10/2020	D - Sponsor Delays	Delay in Contract negotiations & Sponsor Green light	Sponsor
64	19/SC/0622	270469	A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma	No		20			19/08/2019	06/08/2020	14/02/2020	44069	44069		D - Sponsor Delays	Delay in Contract negotiations & Sponsor Green light	Sponsor
65	19/EE/0362	272768	A Randomised Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children (Oxy-PICU)	No		21			11/08/2020	25/08/2020	23/12/2019	04/09/2020	15/09/2020	15/09/2020			

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:	
66	19/YH/0380	273434	A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Ceftazidime Avibactam (CAZ-AVI) in Children From 3 Months to Less Than 18 Years of Age Who are Hospitalized and Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia	No					01/04/2019	23/09/2020	25/02/2020				D - Sponsor Delays	Waiting for sponsor contracts	Sponsor	
67	20/EM/0068	274507	Daily intake of Lactobacillus casei Shirota (LcS) modulates intestinal permeability and decreases circulating levels of endotoxin that associate with both cardiovascular and all-cause mortality in haemodialysis (HD) patients.	No		20			18/12/2019	25/08/2020	03/04/2020	03/09/2020	14/09/2020	21/09/2020				
68	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	No					20/12/2019	11/08/2020	03/04/2020							
69	20/ES/0031	276439	The Effect of Tirzepatide versus Placebo plus standard of care on Major Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)	No					17/02/2020	03/09/2020	30/09/2020							
70	20/SC/0111	276734	DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	No		0			11/12/2019	21/09/2020	12/05/2020	44082	44095	44096				
71	20/NE/0092	277972	AN OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7227166 (A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND INCOMBINATION WITH RO7082859 (CD20-TCB) FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	Yes	25/08/2020	22	26	48	06/03/2020	08/07/2020	05/05/2020	27/07/2020	30/07/2020	30/07/2020				